Aims: Pathogens in lower respiratory tract infections(LRTI) are complex. Conventional microbiological testings(CMTs) are time-consuming and inaccurate. mNGS is widely used to overcome these issues. tNGS, as an emerging NGS technology, has uncertain diagnostic efficacy.Materials and methods: 136 suspected LRTI patients were included from January 2022 to February 2024 from the Department of Respiratory and Critical Care Medicine at Jiangsu Province People’s Hospital,China.We simultaneously submitted the bronchoalveolar lavage fluids (BALFs) for mNGS, tNGS and conventional microbial testing (CMTs) and compared the pathogen diagnostic efficacy of mNGS, and tNGS.Results: A total of 136 patients were included, and there was no statistically significant difference in the detection sensitivity(74.75% VS 78.64%, p>0,05) and specificity(81.82% vs 93,94%,p>0.05) between mNGS and tNGS. However, tNGS has a higher sensitivity(27.94% vs 17.65%,p=0.043)and specificity(88.78% vs 84.82%,p=0.048) for fungi. According to our diagnostic criteria, tNGS successfully identified 3 cases of Pneumocystis jirovecii(P. jirovecii) individually. In addition, both tNGS and mNGS detected chlamydia psittaci whereas CMTs were unable to detect it.Conclusions: tNGS demonstrates diagnostic efficacy for pathogens in lower respiratory tract infections that is comparable to mNGS. However, tNGS has specific advantages in the detection of fungi. Considering the cost-effectiveness of tNGS, it is recommended to implement tNGS clinically for patients with lower respiratory tract infections.
The incidence of invasive pulmonary aspergillosis (IPA) in non-neutropenic patients is increasing. This study aimed to evaluate the clinical outcomes and risk factors for mortality in non-neutropenic IPA patients. We conducted a prospective, multicenter study from August 2020 to February 2024, enrolling 565 patients with suspected IPA. The study cohort comprised 195 IPA (non-neutropenic) cases and 370 non-IPA cases. Peripheral blood and bronchoalveolar lavage fluid (BALF) specimens were collected to measure pentraxin-3 (PTX3) levels. Additionally, demographic data, clinical characteristics, and antifungal therapy of each patient were recorded. We analyzed factors associated with 30- and 90-day mortality. IPA patients exhibited higher mortality rates compared to non-IPA patients, with 30-day rates of 26.15% versus 8.38% ( P < 0.001) and 90-day rates of 34.36% versus 13.24% ( P < 0.001). Higher plasma and BALF PTX3 levels were associated with poor prognosis in IPA patients. ROC curve analysis identified optimal PTX3 thresholds of 4.29 ng/mL in BALF (sensitivity, 67.1%; specificity, 81.4%) and 7.11 ng/mL in plasma (sensitivity, 73.4%; specificity, 82.8%) for predicting mortality. Multivariate Cox regression analysis confirmed PTX3 levels in plasma (hazard ratio [HR] 3.87, 95%CI [1.87–8.00], P <0.001) and BALF (HR 2.40 [1.19–4.84], P = 0.014) were independent prognostic factors for IPA mortality. Additionally, positive galactomannan test results in both BALF and plasma were initially correlated with increased mortality in IPA patients. However, after adjusting for potential confounding factors, this correlation no longer remained statistically significant. In conclusion, PTX3 is a promising prognostic biomarker of mortality in IPA patients. IMPORTANCE: Studies have confirmed the value of pentraxin-3 (PTX3) in the diagnosis of invasive pulmonary aspergillosis (IPA), yet its prognostic significance in IPA remains unclear. This study found that in non-neutropenic IPA patients, plasma and bronchoalveolar lavage fluid (BALF) levels of PTX3 are independently associated with poor outcomes. Furthermore, the optimal cutoff values of PTX3 for predicting a poor prognosis of IPA are 4.29 ng/mL in BALF and 7.11 ng/mL in plasma. These findings could help us better manage IPA in non-neutropenic patients, potentially enhancing the prognosis of patients with this condition.
1 February 2024 in Annals of Clinical Microbiology and Antimicrobials
Objective: This study aims to identify the most effective diagnostic method for distinguishing pathogenic and non-pathogenic Gram-negative bacteria (GNB) in suspected pneumonia cases using metagenomic next-generation sequencing (mNGS) on bronchoalveolar lavage fluid (BALF) samples. Methods: The effectiveness of mNGS was assessed on BALF samples collected from 583 patients, and the results were compared with those from microbiological culture and final clinical diagnosis. Three interpretational approaches were evaluated for diagnostic accuracy. Results: mNGS outperformed culture significantly. Among the interpretational approaches, Clinical Interpretation (CI) demonstrated the best diagnostic performance with a sensitivity of 87.3%, specificity of 100%, positive predictive value of 100%, and negative predictive value of 98.3%. CI’s specificity was significantly higher than Simple Interpretation (SI) at 37.9%. Additionally, CI excluded some microorganisms identified as putative pathogens by SI, including Haemophilus parainfluenzae, Haemophilus parahaemolyticus, and Klebsiella aerogenes. Conclusion: Proper interpretation of mNGS data is crucial for accurately diagnosing respiratory infections caused by GNB. CI is recommended for this purpose.
This study aims to develop and validate an optimized diagnostic model for nonneutropenic invasive pulmonary aspergillosis (IPA) among suspected cases. A cohort of 344 nonneutropenic suspected cases from 13 medical centers (August 2020 to February 2024) was analyzed. The cohort was divided into a training data set (70%) and a testing data set (30%) using stratified sampling based on the IPA diagnosis. Three machine learning models (a regularized logistic regression model, a support vector machine model, and a weighted ensemble model) were developed. SHapley Additive explanation (SHAP) method was used for model interpretation. Six predictor variables were finally selected: sputum Aspergillus culture, Aspergillus -specific IgG, imaging feature of cavity, serum galactomannan, critical condition, and plasma pentraxin 3. The weighted ensemble model, exhibiting the significantly higher specificity of 95.1% in internal cross-validation and 95.7% in testing among the three models, was selected as the optimal prediction model despite comparable discrimination capacity, calibration ability, and clinical applicability across all models. The risk score derived from SHAP values showed a highly significant correlation with the predicted probability of the weighted ensemble model (Spearman ρ = 0.974), achieving an area under the curve of 0.857 in internal cross-validation and 0.871 in external testing. Using the optimal cut-off value of 3, the risk score demonstrated sensitivity (68.8%) and specificity (87.5%) comparable to those of bronchoalveolar lavage fluid galactomannan (cut-off = 1.0). The diagnostic model and risk score could assist in identifying nonneutropenic IPA from suspected cases independently of invasive procedures, thereby enhancing clinical applicability. IMPORTANCE: Although clinicians can screen out suspected cases through medical history inquiries, the diagnosis of nonneutropenic invasive pulmonary aspergillosis (IPA) from suspected cases remains a significant challenge. The study developed a novel diagnostic framework by integrating clinical parameters, imaging features, and laboratory biomarkers using machine learning techniques. The risk score, derived from SHapley Additive explanation values, exhibited a highly significant correlation with the predicted probability of the weighted ensemble model, demonstrating robust discrimination capacity and generalizability. The diagnostic model and risk score could assist in identifying nonneutropenic IPA from suspected cases independently of invasive procedures, thereby enhancing clinical applicability.
The study aimed to describe the clinical features of psittacosis pneumonia and identify risk factors associated with severe psittacosis pneumonia. We retrospectively collected data from patients with psittacosis pneumonia, confirmed by metagenomic next-generation sequencing (mNGS) from January 2022 to June 2024 and analyzed differences between severe and non-severe groups. A total of 24 patients (eight severe/16 non-severe) were diagnosed with psittacosis, and 33.3% had severe psittacosis pneumonia. The levels of white blood cells (WBCs), neutrophils, neutrophil-to-lymphocyte ratio (NLR), hypersensitive C-reactive protein (hs-CRP), and procalcitonin (PCT) and the detection rate of fungi by mNGS were significantly higher in the severe group than in the non-severe group. The length of stay and omadacycline use were longer in patients of the severe group when compared to the non-severe group. Receiver operating characteristic (ROC) curves indicated that NLR had a better predictive value of severe conditions than PCT and hs-CRP. Patients with psittacosis pneumonia have a high rate of severe disease, and NLR may be a useful tool to promptly ascertain the severity of the disease and optimal therapies for better outcomes. IMPORTANCE: This study explores the clinical features of psittacosis pneumonia and identifies key factors that may predict the severity of the disease. By analyzing data from 24 patients diagnosed using metagenomic next-generation sequencing (mNGS), the research uncovers important differences between severe and non-severe cases. The study finds that patients with severe psittacosis pneumonia have elevated levels of white blood cells (WBCs), neutrophils, neutrophil-to-lymphocyte ratio (NLR), C-reactive protein (hs-CRP), and procalcitonin (PCT), as well as a higher detection rate of fungi. Notably, the NLR emerges as a strong predictor of severe disease, suggesting its potential as an early diagnostic tool. These findings provide valuable insights that can help healthcare providers identify high-risk patients more quickly, allowing for timely interventions and improved management of the disease. Ultimately, this research could lead to better outcomes by guiding treatment decisions and enhancing our understanding of psittacosis pneumonia.